Hopp til hovedinnhold
Man vet ikke sikkert hvorfor hepatorenalt syndrom oppstår hos enkelte personer med leversykdom og ikke hos andre.
Man vet ikke sikkert hvorfor hepatorenalt syndrom oppstår hos enkelte personer med leversykdom og ikke hos andre.

Hepatorenalt syndrom

Hepatorenalt syndrom er en komplikasjon til akutt eller kronisk leversykdom og karakteriseres ved akutt nyresvikt og sirkulasjonsforstyrrelser.

Sist revidert:
QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/magetarm/lever/hepatorenalt-syndrom/ 

Hva er hepatorenalt syndrom?

Symptomer

Diagnostikk

Behandling

Prognose

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Hepatorenalt syndrom. Referanselisten for dette dokumentet vises nedenfor.

  1. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Hepatol 2010; 53: 397-417. pmid:20633946 PubMed 
  2. Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020;370:m2687. Published 2020 Sep 14. PMID: 32928750 PubMed 
  3. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361:1279. New England Journal of Medicine 
  4. Angeli P, Gines P, Wong F, et al., International Club of Ascites. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut2015;64:531-7. pmid:25631669 PubMed 
  5. Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56:1310. Gut 
  6. Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019 Oct;71(4):811-822. PubMed 
  7. Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006; 1:1066. PubMed 
  8. Rose BD, Runyon BA. Diagnosis and treatment of hepatorenal syndrome. UpToDate, last updated June 13, 2010. UpToDate 
  9. Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010; 59:988. Gut 
  10. Israelsen M, Krag A, Allegretti AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD011532. The Cochrane Library 
  11. Sagi SV, Mittal S, Kasturi KS, et al. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2010;25:880-885. PMID: 20074149 PubMed 
  12. Ghosh S, Choudhary NS, Sharma AK, et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int. 2013;33:1187-1193 PubMed 
  13. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41: 1282. PubMed 
  14. Wong F, Leung W, Al Beshir M, et al. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transpl 2015; 21:300. PubMed 
  15. Kepros J. Hepatorenal syndrome. BMJ Best Practice, last updated 3 Aug 2021. bestpractice.bmj.com